Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020 ROCHESTER, N.Y., April 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...

Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer,...

Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer’s Disease ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...

Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference Pittsburgh, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...

Alzheimer's Drug Discovery Foundation and Children's Tumor Foundation announce Partnership to Provide Drug Discovery Resources for Research Community NEW YORK, N.Y., March 14, 2014 (GLOBE NEWSWIRE) -- The Alzheimer's Drug Discovery Foundation (ADDF) and The Children's Tumor Foundation (CTF) today announced a partnership to provide CTF's scientific...